Zenas Biopharma says it’s on track to submit applications this year in the U.S. and the European Union seeking approval of its experimental injection therapy obexelimab for treating immunoglobulin G4-related disease (IgG4-RD). In fact, the developer noted that it intends to file a biologics license application to the…
